跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 2026-09-30AI 评分58

EASD26:礼来 amylin-Zepbound 联用方案在肥胖合并糖尿病人群中展示最高减重效果

#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes

AI 导读

在 EASD26 会议上,礼来展示的 amylin-Zepbound 联用方案在肥胖合并糖尿病受试者中取得了迄今最高的减重效果。文章指出该联用方案的表现优于 Wegovy、Zepbound、CagriSema 及 retatrutide。因正文存在付费墙截断,当前材料仅披露了会议名称与初步对比结果。

正文

MI­LAN — For­get We­govy and Zep­bound. Nev­er mind Ca­griSe­ma, and even re­ta­tru­tide. The lat­est big name in obe­si­ty is elo­raTZP.

Da­ta re­vealed Wednes­day show that Lil­ly’s …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news